---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056283"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:57:09.031337+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q1 net loss $28.4M; cash $403.7M; Phase 3 enrollment on track

## Summary
- Net loss of $28.4M ($0.56 diluted EPS) vs $30.1M ($0.80) in Q1 2023.
- Cash and equivalents $403.7M after $287.5M financing; runway through approval and launch.
- Positive 72-week Phase 2b ORIGIN data; 96-week topline results expected Q4 2024.
- Pivotal Phase 3 ORIGIN 3 enrollment estimated complete Q3 2024; data 1H 2025.
- Appointed Robert M. Brenner as CMO and William D. Turner as CDO.

## SEC filing metadata
- accession: 0000950170-24-056283
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017024056283/0000950170-24-056283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017024056283/vera-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056283
- JSON: https://secwatch.observer/filing/0000950170-24-056283.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056283.txt

## Source-grounded claims
- claim_id: 941b723c3da6d934fec3b13bc2d9dc6306108f2f
  claim: Vera Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $28.4 million, or a net loss per diluted share of $0.56, EPS net loss per diluted share of $0.56.
  evidence_excerpt: For the quarter ended March 31, 2024, the company reported a net loss of $28.4 million, or a net loss per diluted share of $0.56, compared to a net loss of $30.1 million, or a net loss per diluted share of $0.80, for the same period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017024056283/0000950170-24-056283-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.